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Background:  Attenuated  vaccinia  virus  strain,  LC16m8,  defective  in the B5R  envelope  protein  gene,  is  used
as a stockpile  smallpox  vaccine  strain  in  Japan  against  bioterrorism:  the  defect  in the  B5R  gene  mainly
contributes  to its highly  attenuated  properties.
Methods:  The  protective  activity  of  LC16m8  vaccine  against  challenge  with  a lethal  dose  of vaccinia  West-
ern Reserve  strain  was  assessed  in wild-type  and  immunodeﬁcient  mice  lacking  CD4,  MHC  class  I, MHC
class  II or  MHC  class  I  and  II antigens.
Results:  The  immunization  with  LC16m8  induced  strong  protective  activity  comparable  to that  of  its
parent  strain,  Lister  (Elstree)  strain,  in wild-type  mice  from  2  days  to 1  year  after  vaccination,  as well as
in immunodeﬁcient  mice  at 2 or 3 weeks  after  vaccination.  These  results  implicated  that  the  defect  in  the
B5R  gene  hardly  affected  the  potential  activity  of  LC16m8  to induce  innate,  cell-mediated  and  humoral
immunity,  and  that LC16m8  could  be effective  in immunodeﬁcient  patients.
Conclusion:  LC16m8  with  truncated  B5  protein  has  an activity  to  induce  immunity,  such  as  innate  immu-
nity  and  subsequent  cell-mediated  and  humoral  immunity  almost  completely  comparable  to the  activity
of its  parental  strain  Lister.
©  2015  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license. Introduction
The success of smallpox eradication by the World Health Orga-
ization (WHO) program in the 1970s is a landmark in the history
f biomedical science. Since the terrorist attack on the World Trade
enter in New York in September 2001, however, concern about
ioterrorism has increased. Among many pathogens that could be
sed potentially in bioterrorism, variola virus is one of the most
ecognized and the most feared. Under such circumstances, seri-
us attempts have been made to restart the development of vaccine
trains, including a vaccinia ACAM2000 clone established from Dry-
ax derived from the New York City Board of Health (NYCBH)
train [1,2], modiﬁed vaccinia Ankara (MVA) and replication-
ncompetent viruses derived from the NYCBH strain [3,4]. However,
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E-mail address: shinmura-ya@kaketsuken.or.jp (Y. Shinmura).
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264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
replication-competent vaccine strains derived from the NYCBH
strain may  have a side effect of inducing myopericarditis [1,2], and
replication-incompetent viruses may  have the potential problem
of relatively poor immunogenicity [3,4].
In the early 1970s, Hashizume et al. [5,6], developed one of
the safest replication-competent vaccines, LC16m8 strain, from the
Lister (Elstree) strain that was used worldwide in the WHO  small-
pox eradication program. Freeze-dried live attenuated smallpox
vaccine of LC16m8 prepared in cell culture has been the sole small-
pox vaccine licensed in Japan since 1975. LC16m8 was selected
as a temperature- sensitive small-plaque- and small-pock-forming
clone [6]. A rabbit skin proliferation study and a neurovirulence
study in which LC16m8 and Lister viruses were inoculated into the
thalamus of cynomolgus monkeys showed very low pathogenicity
of LC16m8 compared with Lister. A clinical evaluation of 90,000
infants immunized during the initial development of LC16m8
from 1973 to early 1976 showed no encephalitis or other seri-
ous adverse events after vaccination. No major differences exist in
the immunogenicity of LC16m8 when compared with conventional
ﬁrst generation smallpox vaccines such as its parental vaccine
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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train Lister. The LC16m8 vaccine is now produced by the Chemo-
ero-Therapeutic Research Institute (Kaketsuken), Japan, and is
tockpiled as a smallpox vaccine against bioterrorism in Japan.
ccording to the November 2013 conclusions and recommenda-
ions of the Meeting of the Strategic Advisory Group of Experts on
mmunization [7], both licensed ACAM2000 (2nd generation vac-
ine) and LC16m8 (3rd generation vaccine) are preferred for the
HO stockpile.
A molecular biological study showed that one gene of envelope
roteins is defective, contributing to smaller plaque size and host
ange and was accordingly called as ps/hr) gene [8]: the ps/hr gene is
 homologue of B5R gene of Copenhagen (CPN) strain, and now this
ene is usually called as B5R gene. The B5R gene product, B5 pro-
ein, is a 42-KDa envelope glycoprotein composed of 317 amino
cids. Vaccinia virus produces two typical types of virion from
ach infected cell called intracellular mature virus and extracellular
nveloped virus (EEV) [9]. B5 protein is necessary for the forma-
ion of EEV, and therefore LC16m8 does not form EEV resulting
n small-plaque size and less spreading ability, which is consid-
red to mainly attribute to its attenuated properties. The analysis
f the full-genome sequence of LC16m8 and its parental strain Lis-
er showed that LC16m8 preserved almost of all the open reading
rames of vaccinia virus except for the disrupted EEV protein B5
10].
A truncated B5 protein (approximately 8 kDa) was  expressed
bundantly in LC16m8-infected cells, and both murine immune
era and human vaccinia virus immunoglobulin recognized the
runcated recombinant B5 protein in antigen-speciﬁc enzyme-
inked immunosorbent assays [11].
Of major concern, however, is whether LC16m8 vaccine has
nough immunogenicity to confer strong protection, because
C16m8 lacks normal type of the B5R gene product, B5 protein,
hich is a target epitope of neutralizing antibodies contributing
o protection in mice [12]. Furthermore, LC16m8 fails to induce
nough anti-B5 antibody responses in the human [13]. Although
revious studies showed that in normal animals and humans
C16m8 keeps strong immunological and protective activity com-
arable to that of its parent strain Lister [6,10,14], whether it keeps
uch activity also in immunodeﬁcient animals remains to be clari-
ed. This point is important in relation to the problem of whether
C16m8 is usable in areas of Africa where many immunodeﬁcient
atients, such as human immunodeﬁciency virus-infected patients,
ive.
To address this problem, this study investigated if LC16m8 with
runcated B5 protein has immunological and protective activity
omparable to that of its parental strain Lister by using wild-type
nd immunodeﬁcient mice lacking CD4, MHC  class I, MHC  class
I antigen or MHC  class I and II antigens. Immunological and pro-
ective activity was assessed in intranasally challenged mice with
 lethal dose of a highly pathogenic vaccinia virus (VACV) strain,
estern Reserve (WR) strain.
. Material and methods
.1. Vaccine and virus strains
Freeze-dried smallpox vaccine (LC16-KAKETSUKEN; LC16m8)
anufactured under good manufacturing practice (GMP)-
ompliant condition by Kaketsuken in cell culture using primary
abbit kidney cells was used as the source of LC16m8 VACV strain.
he vaccine lot used in this study is one (Lot V06) of the lots of
mallpox vaccine stockpiled now in Japan against bioterrorism
sing smallpox. In the current manufacturing process, the occur-
ence of B5R revertant virus which was reported by Kidokoro et al.
15] was well controlled and the content rate in the Lot V06 is (2015) 6112–6119 6113
under 1%. The Lister (Elstree) VACV strain, which was used for the
WHO smallpox eradication program, and the parental strain of
the LC16m8 strain were transferred to Kaketsuken from the Chiba
Serum Institute (Chiba) when this institute closed. UV-inactivated
Lister virus was  prepared by placing 1 × 107 PFU/mL of Lister virus
under UV lumps for approximately 18 h and the inactivation was
conﬁrmed by standard plaque assay. The WR VACV strain (ATCC
VR-1354) used for the challenge was  purchased from the American
Type Culture Collection (ATCC).
2.2. Mice
Wild-type BALB/c mice (female, 4 or 8-week old) were pur-
chased from Charles River Laboratories Japan (Kanagawa). The
following immunodeﬁcient mice (female, 4- to 7-week old) were
purchased from the Taconic Farms (New York): Cd4 (001055-
MF)  CD4-deﬁcient, B2 m (B2MN12-MF) MHC  class I-deﬁcient, Abb
(ABBN12-MF) MHC  class II-deﬁcient, and Abb/2 m (004080-MMF)
MHC  class I and II-double deﬁcient mice.
2.3. Vaccination and WR  challenge
Groups of wild-type or immunodeﬁcient mice received a sin-
gle vaccination at 2.5 × 105 PFU/mouse of LC16m8 or Lister virus
by a 15 times-puncture by using standard bifurcated needles at
the base of the tail or a single intraperitoneal vaccination with
UV-inactivated Lister virus (the virus titer before inactivation was
1 × 107 PFU/mouse). See Table 1 and Table 2 for the number of
mice in each experimental group. After vaccination, the mice
were challenged intranasally with a dose of 105 PFU/mouse or
106 PFU/mouse WR viruses, either of which was amply lethal, at
appropriate time point after vaccination in order to achieve a
highly-lethal condition in the non-immunized animals per each
model. The mice were observed and weighed each day for 14 days
after the challenge. Mice that had showed severe weight loss and
survived to the end of this study, that is, on day 14 after the chal-
lenge were euthanized by heart exsanguination under anesthesia.
Statistical analysis on mean survival time was  done using the log
rank method. All mice studies were approved by the Kaketsuken
Institutional Animal Care and Use Committee.
2.4. Plaque reduction neutralizing (PRN) assay
The level of neutralizing antibody against vaccinia WR virus in
the serum samples was assessed by PRN assay as follows. WR-
virus infected Vero E6 cells (ATCC CRL-1586, purchased from ATCC)
received three times repeated freeze-thaw and the resultant crude
virus ﬂuid was used as a source of WR  virus. This virus ﬂuid
may  contain mainly intracellular mature viruses, with some other
virus forms such as intracellular enveloped viruses, cell-associated
enveloped viruses and extracellular enveloped viruses [9]. WR  virus
at 240 PFU in 0.12 mL  of Eagle’s minimal essential medium (EMEM)
(Nissui, Tokyo) containing 1% fetal bovine serum (FBS) (Life Tech-
nologies, Maryland) was mixed with 0.12 mL of serially diluted
heat-inactivated serum samples collected from test animals and
was incubated at 37 ◦C for 15–18 h. The mixtures were inoculated
in VeroE6 cell (ATCC CRL-1586, purchased from ATCC) monolayers
in 12-well culture plates and were incubated in EMEM contain-
ing 3% FBS and 0.8% agarose ME  (Iwai Chemicals Company, Tokyo)
after 2 h of adsorption. After 4 days of incubation, the number
of observed plaques was  counted. The neutralizing antibody titer
was calculated based on the plaque number by using the Probit
analysis method with Minitab software (Kozo Keikaku Engineering
Inc., Tokyo) and was deﬁned as the reciprocal of the dilution level
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Table 1
Protection against lethal WR challenge at various points after vaccination in wild-type mice.
Time (after vaccination) Vaccination Survival ratio Mean survival time (days) Log-rank test (P)
2 days Non-immunized* 0/6 8.5 –
LC16m8 6/6 >14.0 <0.01
Lister 6/6 >14.0 <0.01
4  days Non-immunized* 0/10 3.9 – <0.01
LC16m8 10/10 >14.0 <0.01 1.00
Lister  10/10 >14.0 <0.01 –
Inactivated Lister 5/10 9.5 <0.01 <0.01
3  weeks Non-immunized* 0/10 4.2 –
LC16m8 10/10 >14.0 <0.01
Lister 10/10 >14.0 <0.01
24  weeks Non-immunized* 0/10 4.9 –
LC16m8 10/10 >14.0 <0.01
Lister 10/10 >14.0 <0.01
1  year Non-immunized* 0/5 4.7 –
LC16m8 5/5 >14.0 <0.01
Lister 5/5 >14.0 <0.01
* The mice were inoculated with LC16m8 diluent.
Table 2
Protection against lethal WR challenge at various points after vaccination in immunodeﬁcient mice.
Mouse model Vaccination Survival ratio Mean survival time (days) Log-rank test (P)
CD4-deﬁcient Non-immunized* 0/4 6.4 –
LC16m8 4/4 >14.0 <0.01
MHC  class I-deﬁcient Non-immunized* 0/5 8.0 –
LC16m8 5/5 >14.0 <0.01
Lister 5/5 >14.0 <0.01
Inactivated Lister 5/5 >14.0 <0.01
MHC  class II-deﬁcient Non-immunized* 1/5 7.2 –
LC16m8 5/5 >14.0 0.014
Lister 5/5 >14.0 0.014
Inactivated Lister 3/5 11.2 0.064
MHC  class I- & II-double deﬁcient Non-immunized* 0/10 8.8 –
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* The mice were inoculated with LC16m8 diluent.
esulting in a 50% reduction of total plaques formed by WR virus
ith no treatment by vaccinated sera.
. Results
.1. Protection in wild-type mice by vaccination with LC16m8
Fig. 1 shows the survival and body weight of wild-type mice
hallenged intranasally with 105 PFU of WR virus on day 2 (A) or
n day 4 (B), with 106 PFU of WR  at 3 weeks (C), 24 weeks (D) and 1
ear (E) after vaccination. Table 1 shows the survival ratio of each
roup, in which the number of mice (5, 6 or 10) in each group is
ndicated.
Both vaccinated and non-vaccinated mice challenged with WR
n day 2 after vaccination showed weight loss. Mice vaccinated
ith either LC16m8 or Lister lost weight from 2 to 6 days after the
hallenge, but they began to recover weight around days 7 and 8
fter the challenge and they all survived. Non-vaccinated mice lost
eight continuously, culminating in death by day 11 after the chal-
enge (Fig. 1A). When mice were challenged with WR  on day 4 after
accination, both LC16m8- and Lister-vaccinated mice showed nei-
her severe nor continuous weight loss, but all non-vaccinated mice
nd half of ultraviolet (UV)-inactivated Lister vaccinated mice lost
eight until they died (Fig. 1B). All mice challenged with WR at 3 13.1 <0.01
 13.2 <0.01
weeks, 24 weeks and 1 year after single dose vaccination showed
almost the same results as for mice challenged on day 4 after vac-
cination (Fig. 1C–E).
These results (1) showed that both LC16m8 attenuated by the
defect of B5R gene and its parental strain Lister had comparable
abilities to protect wild-type mice from very early stages to 1 year
post-vaccination, and (2) implicated that vaccination with both
LC16m8 and Lister conferred at least partial protective immunity on
day 2 after vaccination, and almost complete protective immunity
on day 4 or later until at least 1 year after vaccination.
The neutralizing antibody titers against vaccinia WR virus were
almost not detectable on days 2 to 6 after vaccination (data not
shown), but then increased rapidly until 3 weeks, reaching a plateau
from 8 weeks to 1 year after vaccination in both LC16m8- and Lister-
vaccinated mice (Fig. 2).
3.2. Protection in immunodeﬁcient mice by vaccination with
LC16m8
Because protection by vaccination with LC16m8 was shown in
wild-type mice challenged with WR  as early as 2 days after vaccina-
tion, we speculated the involvement of other immune mechanism
as than humoral immunity in this protection. To study this possi-
bility, we  investigated the effect of LC16m8 vaccination by using
cine 33
v
e
i
b
n
n
L
t
b
F
v
t
o
a
TH. Yokote et al. / Vac
arious immunodeﬁcient mice. Table 2 shows the survival ratio of
ach group, in which the number of mice (5 or 10) in each group is
ndicated.
First, the vaccination effect on CD4-deﬁcient mice was evaluated
y challenging with 106 PFU WR/mouse at 3 weeks after vacci-
ation (Fig. 3A). By day 6 after the challenge, more than 70% of
on-vaccinated mice had severe weight loss and died, while all
C16m8-vaccinated mice survived, suggesting that mice were pro-
ected by innate immunity or CD8+ T-cell mediated immunity or
oth.
ig. 1. Induction of immediate and long-lasting protective immunity in wild- type mice
accinated at 2.5 × 105 PFU of LC16m8 or Lister by using the multiple-puncture method w
oneally  with UV-inactivated Lister virus (the virus titer before inactivation was 1 × 107 P
f  vaccinia-WR strain at 2 days (A) or 4 days (B), and with 106 PFU of vaccinia-WR strain a
nd  weighed each day for 14 days after the challenge.
he number of mice of each group is shown in Table 1. (2015) 6112–6119 6115
Second, the effect on MHC  class I-deﬁcient mice was evalu-
ated by challenging with 105 PFU WR/mouse at 3 weeks after
vaccination (Fig. 3B). All mice vaccinated with LC16m8, live Lis-
ter virus or UV-inactivated Lister virus survived; mice vaccinated
with Lister and LC16m8 showed almost no weight loss. However,
non-vaccinated mice had severe weight loss, and mice vaccinated
with inactivated Lister virus had mild weight loss between >5 and
11 days after the challenge. These results suggest that immune
mechanisms independent of MHC  class I antigens contribute to the
elicitation of a protective response in mice vaccinated with LC16m8
 vaccinated with LC16m8. Groups of mice (4 or 8-week-old, BALB/c, female) were
ith standard bifurcated needles at the base of the tail or were vaccinated intraperi-
FU/mouse). After vaccination, the mice were challenged intranasally with 105 PFU
t 3 weeks (C), 24 weeks (D), or 1 year (E) after vaccination. The mice were observed
6116 H. Yokote et al. / Vaccine 33 (2015) 6112–6119
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Fig. 2. Induction of long-lasting neutralizing antibodies in wild-type mice vacci-
nated with LC16m8. Five or ten mice of each group (4-week-old, BALB/c, female)
were vaccinated at 2.5 × 105 PFU of LC16m8 or Lister by using the multiple-puncture
method with standard bifurcated needles at the base of the tail. The sera collectedFig. 1. 
nd Lister, and live replicating virus is more effective in protection
han inactivated non-replicating virus. Innate immunity or CD4+
 cell-mediated immunity or both are suggested to participate in
rotection.
Third, the effect on MHC-class II-deﬁcient mice was evaluated
y challenging with 106 PFU WR/mouse at 2 weeks after vacci-
ation (Fig. 3C). All mice vaccinated with LC16m8 or live Lister
urvived, but 40% of the mice vaccinated with inactivated Lister
nd 80% of non-vaccinated mice had severe weight loss and died.
hese results strongly suggest that innate immunity or CD8+ T-cell
ediated immunity or both participate in protection by vaccination
ith LC16m8 and Lister.
Fourth, the effect on MHC  class I- and II-double deﬁcient mice
as evaluated by challenging with 105 PFU WR at 2 weeks after vac-
ination (Fig. 3D). All non-vaccinated mice died, while 70% and 60%
f mice vaccinated with LC16m8 and Lister, respectively, survived
ntil 14 days after the challenge. All groups of mice had continu-
us weight loss until 14 days after the challenge, and especially
on-vaccinated mice had the severest weight loss. Notably, live
C16m8 and Lister showed signiﬁcant partial protection, strongly
uggesting that innate immunity contributes to protection.
In this series of experiments, neutralizing antibodies to VACV
R  were undetected at 14 days after WR  challenge in immunized
HC  class II-deﬁcient and immunized MHC  class I and II-double
eﬁcient mice (limit of detection, 1:8) (data not shown).
. DiscussionThis study showed that vaccine strain LC16m8 with truncated
urface B5 protein has protective activity completely comparable to
hat of its parental strain Lister in all experiments using wild-type,
D4-deﬁcient, MHC  class I-deﬁcient, MHC  class II-deﬁcient or MHCfrom the immunized mice at 3 weeks (N = 10), 8 weeks (N = 10), 12 weeks (N = 10),
24  weeks (N = 10) or at 1 year (N = 5) after vaccination were tested for vaccinia
WR-speciﬁc neutralizing antibody titers by PRN assay.
class I- and II- double deﬁcient mice. Notably, no difference existed
between total neutralizing antibody titers induced with LC16m8
and Lister in wild-type mice (Fig. 2), MHC  class II-deﬁcient and MHC
class I- and II- double deﬁcient mice, despite the failure of LC16m8
to induce anti-B5 neutralizing antibody that is protective in mice
[12].
Recently, we  studied the safety of LC16m8 in three immuno-
deﬁcient mouse models (suckling mice, severe combined immu-
nodeﬁcient mice, and wild-type mice treated with cyclosporine)
and showed that LC16m8 showed extremely low virulence in each
of these mouse models when compared with its parental strains,
H. Yokote et al. / Vaccine 33 (2015) 6112–6119 6117
Fig. 3. Induction of strong and comprehensive protective immunity in immunodeﬁcient mice vaccinated with LC16m8. Groups of mice (4 to 7-week-old, female, CD4-
deﬁcient (A), MHC  class I-deﬁcient (B), MHC  class II-deﬁcient (C), or MHC  class I and II-double deﬁcient (D)) were vaccinated at 2.5 × 105 PFU of LC16m8 or Lister by using
the  multiple-puncture method with standard bifurcated needles at the base of the tail or were vaccinated intraperitoneally with UV-inactivated Lister virus (the virus titer
before  inactivation was  1 × 107 PFU/mouse). After vaccination, mice of CD4-deﬁcient (A), MHC  class I-deﬁcient (B), MHC  class II-deﬁcient (C), or MHC  class I and II-double
deﬁcient (D) were challenged intranasally at 106, 105, 106 or 105 PFU of vaccinia-WR strain at 3, 3, 2 or 2 weeks after vaccination, respectively. The mice were observed and
weighed each day for 14 days after the challenge. The number of mice of each group is shown in Table 2.
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ister and LC16mO [16]. These results, together with the results
btained in this study, open the way to use LC16m8 in immu-
odeﬁcient patients. Relevant to this, a notable wide epidemic
f monkeypox was reported in areas of west and central Africa
here a high prevalence of human immunodeﬁciency virus infec-
ion exists [17].
The B5R gene defect is the major factor in attenuation of LC16m8
8,10]. Of concern is that LC16m8 with truncated B5 protein might
ave less immunogenicity and poor protective activity. People
accinated with LC16m8 induce neither extracellular enveloped
irus-neutralizing antibody nor other kinds of antibody to B5 pro-
ein, even though after vaccination the neutralizing antibody to
5 protein is boosted in previously vaccinated individuals [13].
his boosting effect might be due to an abundant expression of
 truncated B5 protein in LC16m8 as mentioned previously but the
ossibility of the occurrence of a revertant virus due to repair of the
utation in the B5R gene [15] is not completely excluded. However,
e use a vaccine preparation with a limited number of propagation
o lessen this risk.
In addition to LC16m8 showing protective activity completely
omparable to that of its parental strain Lister, the following
mmunological evidence strengthens the idea that the B5 protein
efect does not affect all the protective activity of LC16m8. Not only
umoral immunity, but also cell-mediated immunity, contribute
o protection against poxvirus infection [18,19]. Antigens directed
or protective immunity are considered to be numerous because of
he large size of VACV [19]. A total of 49 epitopes recognized by
D8+ T-cells from 35 different VACV antigens were identiﬁed by
creening with peripheral blood mononuclear cells of 31 vaccinees
20]. Fewer studies have been done to identify targets of VACV-
peciﬁc CD4+ T-cells in the murine system (C57BL/6). By using a
andom peptide library, 14 epitopes recognized by CD4+ T-cells
ere identiﬁed [21]. Five known neutralizing antibody target anti-
ens exist: L1, H3, A27, D8 and B5. Interestingly, antibodies against
he A33 surface protein are protective, but are not neutralizing [19].
o conclude, even if LC16m8 fails to induce a neutralizing anti-
ody against B5 protein, both cell-mediated and humoral immune
esponses directed to many antigens other than B5 protein of large-
ize VACV should fully compensate the defect of LC16m8 because
f truncated B5 protein.
From the results that CD4-deﬁcient mice, MHC  class I-deﬁcient
ice and MHC  class II-deﬁcient mice were protected for at least
4 days after the challenge (Fig. 3A–C), one or a combination of
umoral, CD4+ T-cell-mediated and CD8+ T-cell-mediated immu-
ity is suggested to be enough for protection. Poor protection of
HC class I and II-double deﬁcient mice (Fig. 3D) suggests that
ither CD4+ T-cell-mediated immunity or CD8+ T-cell-mediated
mmunity is essential for protection. Although neutralizing anti-
ody titers in CD4-deﬁcient mice and MHC  class I-deﬁcient mice
ere not examined in the present study, if these results are
btained in the future, the results may  strengthen our hypothesis.
Other clinical studies support our view. Administration of
C16m8 to healthy adults who were vaccinia-naïve is associ-
ted with high levels of vaccine take and seroconversion (Saito
t al. [22]). Previously vaccinated healthy adults yield an effec-
ive booster response: a phase I/II clinical trial of LC16m8 vaccine
chieved anti-vaccinia, anti-variola, and anti-monkeypox neutral-
zing antibody titers >1:40, and induced robust cellular immune
esponses as assessed by a lymphocyte proliferation test [23].
Gordon et al. [24] investigated the immunologic basis of the
ontainment of vaccinia in the skin with the goal to identify safer
accines for smallpox. Macaques were depleted systemically of or B cells and vaccinated with either Dryvax or an attenuated
accinia vaccine, LC16m8. B cell depletion did not affect the size
f skin lesions induced by either vaccine. However, while deple-
ion of both CD4+ and CD8+ T cells had no adverse effects on (2015) 6112–6119
LC16m8-vaccinated animals, it caused disseminated vaccinia in
macaques immunized with Dryvax. Furthermore, as both Dryvax
and LC16m8 vaccines protect healthy macaques from a lethal mon-
keypox intravenous challenge, their data identify LC16m8 as a
safer and effective alternative to ACAM2000 and Dryvax vaccines
for both healthy and immunocompromised individuals. This study
strongly support the idea that CD4+ and CD8+ T cell- immunity
plays crucial roles in protective ability, and that the lack of normal
B5 protein does not affect this ability.
Our study also strongly suggested that LC16m8 induced innate
immunity partially contributing to protection at the early stages
after vaccination because vaccination with LC16m8 protected wild-
type mice challenged on 2 to 4 days after vaccination (Fig. 1A,
B): humoral, as well as CD4+ and CD8+ T-cell mediated, immune
responses, if any, may  not be induced or are very poor in these
stages. Vaccination with LC16m8 or Lister induced comparable par-
tial protection in MHC  class I- and II-double deﬁcient mice lacking
both T-cell- and B-cell-mediated immunity and strongly supports
the above speculation of the contribution of innate immunity to
immediate protection (Fig. 3D).
Mice infected with various viruses, including VACV, induce nat-
ural killer (NK) cell activity on day 1 to day 10 after vaccination
[25] and is consistent with the speculation from our results that
protective activity of LC16m8 observed at the early stages after vac-
cination in wild-type mice and in various immunodeﬁcient mice is
given by innate immunity (Figs. 1, 3). Microorganisms, like viruses
that invade a vertebrate host, are initially recognized by the innate
immune system through pattern-recognition receptors. Several
classes of these receptors, including Toll-like receptors and cyto-
plasmic receptors, recognize distinct microbial components and
induce the release of interferon- and interferon- [26].
Induction of innate immunity by live LC16m8 virus is consid-
ered to activate cell-mediated and humoral immunity, as shown
by good protection of mice against lethal challenge by at least 1
year after vaccination (Figs. 1, 2). VACV antigens present on the cell
surface induce acquired immunity, including humoral and T-cell-
mediated immunity, whereas VACV antigens inside cells contribute
to the production of interferons, pro-inﬂammatory cytokines and
chemokines, and NK cells responsible for innate immunity [27,28].
5. Conclusion
This study strongly suggested that LC16m8 with truncated B5
protein has an activity to induce innate immunity and subsequent
cell-mediated and humoral immunity almost completely compa-
rable to the activity of its parental strain Lister.
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